Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PH-905
- Development stage
- Preclinical
- Lead developer
- Phio Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ex Vivo
01
Overview
PH-905 is a self-delivering small interfering RNA (siRNA) compound developed using Phio Pharmaceuticals' INTASYL technology. It specifically targets and silences the Cbl-b gene in primary natural killer (NK) cells. Cbl-b is known to limit NK cell activation; by silencing this gene, PH-905 enhances NK cell proliferation, activation, and cytotoxicity against tumor cells. Preclinical data show that treatment with PH-905 increases the anti-tumor response of NK cells without negatively impacting their viability. The compound is being investigated as an adjunct to improve adoptive cell therapy (ACT), particularly for hematological malignancies such as leukemia[1].
- Brand names
- INTASYL PH-905
- Other names
- INTASYL Compound PH-905
02
Targets
CBLB (CBL-B)
Beyond the preview
Go deeper on PH-905.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PH-905.